Sign In
22 Oct 2012 07:00
For immediate release 22 October 2012
ABCAM PLC
("Abcam" or "the Company")
AGM Statement
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, is this morning holding its Annual General Meeting.
Michael Redmond, Abcam's Chairman, will make the following statement:
"Last month, in our preliminary results, we highlighted the challenges faced in our Western markets as Governments address fiscal deficits, including the effect of uncertainty about future levels of research funding on researchers' spending. These challenges remain a feature of our markets, particularly in the US ahead of the election later this year.
"Despite this backdrop, the Board believes that Abcam is well positioned to deliver continued growth. The integration of the Epitomics reagents business is proceeding successfully and the Board is pleased with the Company's profitability in the first three months of the financial year."
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer Jeff Iliffe, Chief Financial Officer www.abcam.com | |
Numis Securities - Nominated Advisor and Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Advisor James Black - Corporate Broking | |
Peel Hunt LLP - Joint Broker | + 44 (0) 207 418 8900 |
Andy Crossley - Corporate Broking | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.
Abcam now has an online catalogue of over 98,000 products sourced from more than 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website, www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.
Follow the stocks
